Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19) | Zendy

Julie Boucau | Zendy; Rockib Uddin | Zendy; Caitlin Marino | Zendy; James Regan | Zendy; James P. Flynn | Zendy; Manish C. Choudhary | Zendy; Geoffrey Chen | Zendy; Ashley Stuckwisch | Zendy; Josh Mathews | Zendy; May Y. Liew | Zendy; Arshdeep Singh | Zendy; Zahra Reynolds | Zendy; Surabhi Iyer | Zendy; Grace Chamberlin | Zendy; Tammy D. Vyas | Zendy; Jatin M. Vyas | Zendy; Sarah E. Turbett | Zendy; Jonathan Z. Li | Zendy; Jacob E. Lemieux | Zendy; Amy K. Barczak | Zendy; Mark J. Siedner | Zendy

Open Access

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Author(s) -

Julie Boucau,

Rockib Uddin,

Caitlin Marino,

James Regan,

James P. Flynn,

Manish C. Choudhary,

Geoffrey Chen,

Ashley Stuckwisch,

Josh Mathews,

May Y. Liew,

Arshdeep Singh,

Zahra Reynolds,

Surabhi Iyer,

Grace Chamberlin,

Tammy D. Vyas,

Jatin M. Vyas,

Sarah E. Turbett,

Jonathan Z. Li,

Jacob E. Lemieux,

Amy K. Barczak,

Mark J. Siedner

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac512

Subject(s) - medicine , ritonavir , covid-19 , virology , coronavirus , viral load , viral disease , virus , immunology , disease , infectious disease (medical specialty) , outbreak , antiretroviral therapy

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research